Home » Topics » Regulatory » EMA

EMA
RSS

European CHMP recommends approval of Lojuxta

June 3, 2013

European CHMP recommends approval of pomalidomide for rrMM

June 3, 2013

BioMarin's applications for Vimizim accepted by both FDA and EMA

May 31, 2013

EMA grants orphan drug designation to Sucampo's retinitis pigmentosa therapeutic

May 30, 2013

EMA grants accelerated assessment to Gilead's MAA for sofosbuvir

May 22, 2013

EMA's CHMP recommends restricting use of Protelos/Osseor

April 29, 2013

European CHMP recommends conditional approval of Erivedge for BCC

April 29, 2013

CHMP issues positive opinion for approval of Nuedexta

April 29, 2013

EMA committee recommends approval of Xtandi

April 29, 2013

European CHMP recommends approval of avanafil for erectile dysfunction

April 29, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 4, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...